Aug 30, 2026 · 31 min
Cancer vaccine faces a political test in America
The Global Story: Will the new cancer vaccine survive RFK Jr’s America?
A personalized mRNA treatment could help prevent skin cancer from returning, but its future depends on public trust and continued scientific investment.
- 1Personalized mRNA vaccines train the immune system to recognize targets unique to a patient’s tumor.
- 2COVID-19 accelerated mRNA research after decades of groundwork, shifting the technology from cancer treatment toward pandemic response.
- 3Political opposition and U.S. funding cuts could slow cancer research, push scientists abroad, and weaken future pandemic preparedness.
Don't miss
Tom Whipple connects the vaccine’s potential to prevent cancer recurrence with the broader risk that political resistance could weaken future pandemic preparedness.
The brief
A personalized mRNA vaccine aims to prevent skin cancer from returning by training each patient’s immune system to recognize targets in their tumor.
Science broadcaster Tom Whipple explains why this is not a conventional preventive vaccine, but a treatment tailored to the biology of an existing cancer.
The story follows Katalin Karikó’s long path from difficult early research to collaboration with BioNTech, showing how decades of work enabled mRNA’s breakthrough.
COVID-19 accelerated mRNA development and public awareness, while also intensifying disputes over vaccine safety, effectiveness, and trust.
The central question is political as much as scientific: whether opposition and U.S. funding cuts will undermine cancer research and future pandemic preparedness.
Featuring
Mentioned
Robert F. Kennedy Jr.
Food and Drug Administration
BBC World ServiceBooks & mentions
Listen to the full episode and explore every guest, topic, and moment on PodLume.